Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wright launches biologic grafting system:

This article was originally published in Clinica

Executive Summary

Wright Medical, of Arlington, Tennessee, has released a new, minimally-invasive biologic grafting system onto the US market. The product is intended for use in core decompression surgical procedures. Core decompression is used to treat patients with early stage avascular necrosis (AVN) of the hip. The biologic grafting system combines the new X-Ream expandable reamer with Wright's proprietary Pro-Dense injectable graft. To use the system, the surgeon first drills a small channel through the "neck" of the femur, to access and "decompress" the diseased bone. The X-Ream device is then inserted into the channel, and the tip expanded and rotated, removing the necrotic bone. The Pro-Dense graft is then injected into the space, in order to regenerate healthy bone. Further launches in other countries are slated for early 2008.

You may also be interested in...



Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.

Topics

UsernamePublicRestriction

Register

MT050421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel